AU2001257325A1 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
AU2001257325A1
AU2001257325A1 AU2001257325A AU5732501A AU2001257325A1 AU 2001257325 A1 AU2001257325 A1 AU 2001257325A1 AU 2001257325 A AU2001257325 A AU 2001257325A AU 5732501 A AU5732501 A AU 5732501A AU 2001257325 A1 AU2001257325 A1 AU 2001257325A1
Authority
AU
Australia
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257325A
Inventor
James Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU2001257325A1 publication Critical patent/AU2001257325A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001257325A 2000-04-28 2001-04-26 Cancer treatment Abandoned AU2001257325A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79198600A 2000-04-28 2000-04-28
US56270900A 2000-04-28 2000-04-28
US09791986 2000-04-28
US09562709 2000-04-28
PCT/US2001/013543 WO2001083457A2 (en) 2000-04-28 2001-04-26 Benzimidazole-2-carbamates and their use in cancer treatment

Publications (1)

Publication Number Publication Date
AU2001257325A1 true AU2001257325A1 (en) 2001-11-12

Family

ID=27073041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257325A Abandoned AU2001257325A1 (en) 2000-04-28 2001-04-26 Cancer treatment

Country Status (3)

Country Link
US (1) US20010047021A1 (en)
AU (1) AU2001257325A1 (en)
WO (1) WO2001083457A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
EP1620564A4 (en) * 2003-04-18 2008-03-12 Cytovia Inc Methods of treating diseases responsive to induction of apoptosis and screening assays
KR101287917B1 (en) 2004-12-06 2013-07-23 뉴사우스 이노베이션즈 피티와이 리미티드 Treatment for Cancer
CN107102141A (en) * 2016-02-23 2017-08-29 中国科学院生物物理研究所 Molecular marked compound CD71 and Endometrial Carcinomas diagnosis, the application by stages and in prognosis
WO2023191536A1 (en) * 2022-03-30 2023-10-05 고려대학교 산학협력단 Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499761A (en) * 1964-07-20 1970-03-10 Gaf Corp Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents
ZA962879B (en) * 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers

Also Published As

Publication number Publication date
US20010047021A1 (en) 2001-11-29
WO2001083457A2 (en) 2001-11-08
WO2001083457A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
AU2002223827A1 (en) Well treatment
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2020501A (en) Chemotherapy treatment
AU2001252599A1 (en) Remedies for cancer
AU2001280598A1 (en) Anti-occlusion catheter
AUPQ923100A0 (en) Treatment of prostate cancer
AU2001277711A1 (en) Remedies for cisplatin-tolerant cancer
AU2002308642A1 (en) Methods for treating cancer
AU5547000A (en) Novel treatment
AU2002227925A1 (en) Human beta-defensin-3
AU2001236929A1 (en) Surface treatment
AU4556800A (en) Novel treatment
AU2002335667A1 (en) Modified reoviral therapy
AU2001257325A1 (en) Cancer treatment
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
GB0026015D0 (en) Cancer treatment
AU2001261324A1 (en) Psoriasis treatment
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU2002331816A1 (en) A cancer treatment system
AU2001289127A1 (en) Tumor treatment
AU2001257168A1 (en) Cancer treatment
AU2002351382A1 (en) Combination cancer therapy
AU2001292897A1 (en) Novel therapy